Tempus AI agrees to acquire Personalis in $1.5bn precision oncology deal built around a $46 floor price

Tempus AI, Inc. (NASDAQ: TEM) has entered into a definitive agreement to acquire Personalis, Inc. (NASDAQ: PSNL) in a stock-plus-optional-cash transaction valued at approximately $1.5 billion enterprise value, net of Tempus AI, Inc.’s existing 12.5 percent ownership interest.

Personalis, Inc. shareholders will receive consideration of $16.25 per share, a 6 percent premium to the 17 July 2026 closing price and a 28 percent premium to the unaffected 30-day volume-weighted average price.

The deal is structured as a two-step merger under Section 368(a) of the Internal Revenue Code, with a floating exchange ratio capped at a maximum of 0.3356 Tempus AI, Inc. Class A shares per Personalis, Inc. share, and Tempus AI, Inc. holding the option to pay up to 50 percent of the consideration in cash from balance-sheet cash and existing credit facilities.

Personalis, Inc. can terminate the agreement if the Tempus AI, Inc. Parent Stock Price finalises below a $46.00 Lower Floor Price before closing, a clause that took on immediate significance when Tempus AI, Inc. shares fell as much as 9.2 percent on the announcement to $47.65, within about $1.65 of the trigger.

The central question for institutional readers is whether the strategic logic of consolidating molecular residual disease testing into Tempus AI, Inc.’s precision oncology platform can be preserved under a share-price collar that leaves market volatility itself as a live source of completion risk between now and the expected late-2026 or early-2027 close.

Why is the $16.25 Personalis, Inc. offer structured with a $46 Tempus AI, Inc. floor price PSNL can walk from?

The Lower Floor Price is the most consequential structural feature of the deal. Personalis, Inc.’s right to terminate the merger agreement if Tempus AI, Inc.’s Parent Stock Price is finalised below $46.00 before closing is a target-side protection against consideration erosion during the four to nine months between signing and completion. Under a stock-based deal with a floating exchange ratio capped at 0.3356, Personalis, Inc. shareholders bear the risk of Tempus AI, Inc. share-price declines beyond a point. The floor gives them the right to walk if the acquirer’s stock cannot support the promised $16.25 headline value in a credible way.

That optionality is not free for Tempus AI, Inc. It means the acquirer needs to defend a share-price floor while integrating a lower-margin, cash-burning genomics platform, at a moment when investors are still processing the strategic rationale and the dilution implications. Monday’s price reaction reduced Tempus AI, Inc.’s market capitalisation by approximately $730 million and pushed the shares within striking distance of the trigger. If the Parent Stock Price recovers meaningfully into the Personalis, Inc. shareholder vote, the collar becomes theoretical. If it does not, the collar becomes a live deal risk that Personalis, Inc.’s board will need to weigh carefully before recommending the transaction.

What does Personalis, Inc.’s NeXT Personal MRD platform add to Tempus AI, Inc.’s precision oncology stack?

Personalis, Inc.’s NeXT Personal is a tumour-informed molecular residual disease test that uses whole-genome sequencing to build a personalised genetic signature of a patient’s tumour, then uses ultrasensitive blood-based liquid biopsies to detect residual circulating tumour DNA after treatment or during monitoring. Molecular residual disease testing is intended to catch traces of cancer that are too small to appear on imaging, which is a distinct and increasingly important layer in the oncology diagnostic stack. NeXT Personal has industry-leading sensitivity claims for detecting small traces of circulating tumour DNA, and Personalis, Inc. has secured Medicare coverage in three indications with additional coverage anticipated.

For Tempus AI, Inc., the strategic fit is complementary rather than duplicative. Tempus AI, Inc.’s existing precision oncology platform supports diagnosis and treatment selection using multimodal data and AI, but its coverage of the recurrence-monitoring segment of the cancer care continuum was less complete. Adding NeXT Personal extends the platform from diagnosis and treatment selection through post-treatment surveillance and recurrence detection, which in oncology accounts for a significant share of lifetime patient encounters. The deal builds on a November 2023 partnership under which Tempus AI, Inc. invested in Personalis, Inc. and commercialised NeXT Personal, and Bloomberg Intelligence analyst Jonathan Palmer has flagged the strength of that pre-existing agreement, which was already scheduled to run through 2029.

How does the $1.5 billion enterprise value stack up against Personalis, Inc.’s revenue run rate and MRD market opportunity?

Personalis, Inc. reported preliminary second-quarter 2026 revenue of $22.4 million with 10,384 clinical tests performed, a 33 percent quarter-on-quarter increase in test volume. Annualising that Q2 revenue implies a run rate of approximately $89.6 million. Against the $1.5 billion enterprise value net of Tempus AI, Inc.’s existing 12.5 percent ownership stake, the transaction values Personalis, Inc. at approximately 16.7 times that annualised revenue run rate. Full-year 2025 revenue of $69.6 million and EBITDA of negative $78.01 million provide the trailing context, and the acquisition is being underwritten on rapidly accelerating volumes rather than on trailing profitability.

The valuation looks aggressive against a Tempus AI, Inc. price-to-sales ratio of approximately 5.4 based on the 2026 revenue guidance midpoint of $1.595 billion. It looks more defensible against the MRD market opportunity that Tempus AI, Inc. has framed as a $20 billion emerging category. Whether that framing holds depends on the pace of reimbursement expansion, physician adoption and competitive dynamics against incumbent MRD platforms from Natera and Guardant Health. The Personalis, Inc. board’s recommendation and the price target that Needham raised to $17 from $12 as recently as 17 July 2026 both suggest that the target-side view of the standalone valuation was already moving higher into the announcement.

Why did Tempus AI, Inc. shares drop 9 percent on the deal day, and how close did they come to the floor?

The Tempus AI, Inc. share-price reaction was the day’s most watched variable. Shares fell as much as 9.2 percent to $47.65 in New York on Monday, reducing market capitalisation by approximately $730 million. That drop reflected several concurrent investor concerns. The dilution implication of a primarily stock-funded acquisition of a cash-burning genomics platform is the most direct. The integration and reimbursement execution risk on a market opportunity that remains substantially in front of, rather than behind, the acquirer is the next concern. And the fact that Personalis, Inc. carries negative trailing EBITDA of about $78 million means the transaction is not accretive to Tempus AI, Inc.’s stated 2026 adjusted EBITDA target of approximately $65 million.

The proximity to the $46 floor was the tactical concern. At $47.65, Tempus AI, Inc. traded within roughly 3.5 percent of the Lower Floor Price, meaning a modest further decline could put Personalis, Inc. in a position to reconsider its recommendation. Morgan Stanley described the strategic logic as sound despite financial hurdles, Needham characterised the intraday slide as a market misread, and Lake Street downgraded Personalis, Inc. to Hold from Buy on the day. The wide analyst dispersion is itself informative: the deal is not obvious to the sell side either, and its economic delivery is inseparable from what happens to Tempus AI, Inc.’s equity between now and closing.

How does the two-step Aviary Development, Inc. and Toucan Development, LLC merger structure protect the tax and legal architecture?

The merger agreement uses a two-step structure that is designed to qualify as a tax-free reorganisation under Section 368(a) of the Internal Revenue Code. Aviary Development, Inc., a Delaware corporation and a wholly-owned Tempus AI, Inc. subsidiary, is the first-step Merger Sub. Toucan Development, LLC, a Nevada limited liability company and a wholly-owned Tempus AI, Inc. subsidiary, is the second-step Merger Sub and, at the end of the sequence, the surviving entity that holds the acquired Personalis, Inc. business as a wholly-owned unit of Tempus AI, Inc.

For Personalis, Inc. shareholders, the tax-free treatment on the stock component is a material benefit, since it defers the tax consequences of the transaction until the ultimate disposal of the acquired Tempus AI, Inc. shares. The 50 percent cash cap on Tempus AI, Inc.’s optional cash election is calibrated to preserve the Section 368(a) reorganisation qualification, which typically requires that a minimum threshold of the total consideration is delivered in acquirer stock. The exchange ratio is determined by a formula based on a 15-day volume-weighted average Parent Stock Price closer to closing, subject to the 0.3356 maximum cap.

What are the $76.8 million symmetrical termination fees signalling about regulatory and completion risk?

The merger agreement provides for a Personalis, Inc. termination fee of approximately $76.8 million payable in specified circumstances, most commonly a switch to a superior proposal, alongside a reverse termination fee of approximately $76.8 million payable by Tempus AI, Inc. if the transaction fails under specified regulatory or timing conditions. The symmetry of the fees is worth flagging. In transactions where regulatory risk is asymmetric or where one party has materially more to lose from failure, termination fees are often calibrated differently. A symmetrical construct suggests both boards judge the completion risk as roughly balanced between market conditions on the Tempus AI, Inc. side and superior-proposal risk on the Personalis, Inc. side.

The outside date is 20 April 2027, subject to automatic extensions in specified circumstances. That timeline gives roughly nine months from signing for the required Personalis, Inc. shareholder vote, antitrust and other regulatory approvals, and completion of the two-step merger mechanics. Regulatory review will focus on the horizontal overlap between the two companies’ existing precision oncology and MRD activities, and the fact that Tempus AI, Inc. already owns approximately 12.5 percent of Personalis, Inc. and has commercialised NeXT Personal since 2023 provides useful evidence that the two businesses have historically been complements rather than pure substitutes.

Where does the deal sit within the broader precision oncology and AI diagnostics consolidation trend?

The transaction is part of a wider consolidation wave in AI-enabled precision oncology. Multiple integrated diagnostic and data platforms are being assembled through a combination of acquisitions, strategic investments and commercial partnerships, as operators race to secure end-to-end coverage across diagnosis, treatment selection and surveillance. The strategic pattern mirrors what happened in the medical imaging and electronic health records categories a decade ago, where scale platforms consolidated once-independent point solutions.

The Tempus AI, Inc. and Personalis, Inc. combination is one of the larger transactions to combine an established AI-oriented data platform with a specialised MRD provider, and the fact that the two companies were already commercial partners since 2023 mitigates some integration risk that other pairings might face. The read-through for peers in the MRD category, including Natera, Guardant Health and Exact Sciences, is that scale platforms are willing to underwrite premium valuations for differentiated MRD capabilities, though the collar structure signals that the market is not yet willing to accept those valuations without target-side protections.

What are the Personalis, Inc. shareholder-vote and regulatory gates between now and the late-2026 close target?

Between now and closing, the meaningful gates are Personalis, Inc. shareholder approval, antitrust and other regulatory clearances, and the S-4 registration statement and Schedule 13E-3 filings that will formalise the disclosure package for shareholders. Personalis, Inc. shareholders will vote on the merger with the benefit of the fairness opinion and background disclosures in the proxy, and the target-side board has already unanimously approved the transaction. The no-shop covenant restricts Personalis, Inc. from soliciting alternative bids, though the board retains fiduciary-out and matching-rights provisions that allow it to consider and pivot to a superior proposal.

Regulatory review will proceed through customary US antitrust filings and any applicable foreign jurisdiction reviews. Given that the two companies have operated as commercial partners since 2023 without regulatory objection, and given Tempus AI, Inc.’s pre-existing 12.5 percent ownership stake, structural regulatory concerns look manageable. Timing risk is more about administrative pace than substantive competition analysis. The 20 April 2027 outside date provides a comfortable but not unlimited runway.

How is Tempus AI, Inc. positioned heading into the 30 July Q2 2026 results release?

Tempus AI, Inc. shares carry a 52-week range of $41.73 to $104.32, and Monday’s slide to $47.65 places the stock in the lower quarter of that range. Market capitalisation stood at approximately $8.67 billion before the announcement and roughly $8 billion after the drop. The company will report second-quarter 2026 results on 30 July 2026, and consensus expectations call for a loss per share of approximately $0.20 on revenue of approximately $380.24 million, up from $314.63 million in the prior year. Cash and equivalents totalled $521.17 million as of 31 March 2026, providing balance-sheet capacity for a 50 percent cash election under the deal terms.

Sell-side sentiment ahead of the deal had been cautiously constructive, with Guggenheim Securities raising its price target to $65 on 16 July 2026, Needham maintaining a Buy with a $75 target on 1 June 2026 and Freedom Capital initiating with a Hold at $59 on 1 July 2026. The average consensus price forecast was approximately $66.82. The 30 July results release will now double as the first opportunity for management to address the deal rationale in detail, defend the share-price setup against the $46 floor and update investors on the standalone operating trajectory. The market’s response to that call will shape the deal’s completion probability at least as much as the underlying strategic thesis.

Key takeaways from the Tempus AI, Inc. and Personalis, Inc. $1.5 billion precision oncology deal

• Tempus AI, Inc. has agreed to acquire Personalis, Inc. at $16.25 per share, valuing the transaction at approximately $1.5 billion enterprise value, net of Tempus AI, Inc.’s existing 12.5 percent ownership interest.
• The consideration is structured as a floating stock exchange ratio capped at a maximum of 0.3356 Tempus AI, Inc. shares per Personalis, Inc. share, with Tempus AI, Inc. holding the option to elect up to 50 percent of the total consideration in cash.
• The offer represents a 6 percent premium to the 17 July 2026 closing price and a 28 percent premium to the unaffected 30-day volume-weighted average price.
• Personalis, Inc. has the right to terminate the agreement if Tempus AI, Inc.’s Parent Stock Price is finalised below a $46.00 Lower Floor Price before closing, which is a live variable given Monday’s drop to $47.65.
• The deal is structured as a two-step merger under Section 368(a) of the Internal Revenue Code, using Tempus AI, Inc.’s subsidiaries Aviary Development, Inc. and Toucan Development, LLC as the merger vehicles.
• Symmetrical termination fees of approximately $76.8 million apply on both sides, and the outside date is 20 April 2027, subject to automatic extensions.
• Strategic rationale centres on integrating Personalis, Inc.’s NeXT Personal molecular residual disease test into Tempus AI, Inc.’s AI-enabled precision oncology platform, extending coverage across the cancer care continuum from diagnosis through recurrence monitoring in a market Tempus AI, Inc. sizes at $20 billion.
• Personalis, Inc. reported preliminary second-quarter 2026 revenue of $22.4 million with 10,384 clinical tests, a 33 percent quarter-on-quarter increase in test volume, and holds Medicare coverage in three MRD indications with more anticipated.
• Tempus AI, Inc. shares fell as much as 9.2 percent to $47.65 on the announcement, reducing market capitalisation by approximately $730 million, with sell-side analysts split between Morgan Stanley and Needham defending the strategic logic and Lake Street downgrading Personalis, Inc. to Hold.
• The most immediate catalyst for both stocks is the Tempus AI, Inc. second-quarter 2026 results release on 30 July 2026, at which management will address the deal rationale in detail and the market will judge the share-price setup against the $46 floor.